Corbus Pharmaceuticals Holdings (CRBP) said Tuesday that CRB-701 has received fast track designation from the US Food and Drug Administration for the treatment of relapsed or refractory metastatic cervical cancer.
The company said the designation aims to facilitate the development and hasten the review of drugs that have the "potential to fill an unmet medical need."
Corbus said it recently completed enrollment of the dose escalation part of its phase 1 clinical trial of CRB-701 and expects to release the first data from the dose escalation clinical study in Q1.
Corbus shares were up 5.9% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。